Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 7Completed 5Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Injections 39Carboplatin 33Capecitabine 24Paclitaxel 23Cisplatin 23Docetaxel 22pembrolizumab 21Oxaliplatin 21Gemcitabine 21Bevacizumab 19Pemetrexed 18Fluorouracil 13Irinotecan 12Cyclophosphamide 11osimertinib 9Nivolumab 9Dexamethasone 8Topotecan 7Leucovorin 7130-nm albumin-bound paclitaxel 7venetoclax 6toripalimab 6tislelizumab 6regorafenib 6lenvatinib 6fludarabine 6Doxorubicin 6Cetuximab 6daratumumab 5atezolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × INDUSTRY × ceralasertib × Clear all
NCT06754761 2025-01-01

Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib

AstraZeneca

Phase 1 Not yet recruiting
8 enrolled
GynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡